| Variable | Treatment group | p value | |||
|---|---|---|---|---|---|
| Overall | Following docetaxel chemotherapy | Without prior docetaxel chemotherapy | |||
| Duration of therapy with primary medication | |||||
| Abiraterone, mo | Mean (95% CI) | 6.4 (5.9-6.9) | 6.0 (5.2-6.7) | 6.6 (5.9-7.3) | 0.7 |
| Median (IQR) | 6.0 (3.0-8.3) | 5.3 (3.0-7.5) | 5.9 (3.0-9.0) | 0.7 | |
| Abiraterone, d | Mean (95% CI) | 191 (176-207) | 178 (157-200) | 197 (177-217) | 0.7 |
| Median (IQR) | 176 (90-249) | 158 (90-224) | 178 (90-270) | 0.7 | |
| Chemotherapy, no. of cycles | Mean (95% CI) | 1.6 (1.3-1.9) | 4.9 (4.3-5.5) | - | - |
| Median (IQR) | 0 (1.0-2.0) | 4.0 (3.0-7.0) | - | - | |
| Hospital days | |||||
| Prostate-cancer-related | Mean (95% CI) | 11.4 (8.6-14.2) | 13.2 (9.2-17.1) | 10.5 (6.8-14.2) | 0.006 |
| Median (IQR) | 3 (0-15) | 7 (0-18) | 1 (0-13.5) | 0.01 | |
| All causes | Mean (95% CI) | 11.8 (9.0-14.6) | 13.7 (9.7-17.7) | 10.9 (7.2-14.6) | 0.001 |
| Median (IQR) | 4 (0-15) | 7 (0-20) | 2 (0-14) | 0.012 | |
Note: CI = confidence interval, IQR = interquartile range.